Berberine prevents early onset af after off-pump coronary artery bypass grafting

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028839

Enrollment

Unknown

Registered

2020-01-05

Start date

2020-01-03

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

experimental group:Berberine orally

control group:Placebo orally

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)Aged 80-35 years, Sex Unlimited; 2)Pre-operation was sinus rhythm, no history of atrial fibrillation and atrial Arrhythmia, no history of Bradycardia; 3)Off-pump coronary artery bypass grafting with internal mammary artery and / or Great Saphenous Vein; no history of congenital heart defect or valvular disease; 4) EF > 40%; 5)First Time Heart Operation; 6)Good compliance, to complete the follow-up.

Exclusion criteria

Exclusion criteria: 1)Known to Berberine allergy or intolerance or have contraindications; 2)The results of liver and kidney function damage were 3 times higher than the upper limit of normal value, serious lung disease and contraindication of operation 3)Patients with atrial fibrillation, sick Sinus Syndrome, atrioventricular block, patients requiring class I and Class III antiarrhythmic agent; 4)Atrial fibrillation ablation history, pacemaker implantation history; 5)Patients with other diseases requiring radiotherapy, chemotherapy and long-term hormone therapy;Recent myocardial infarction; 6)Those who have participated in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Incidence of atrial fabrilation (lasting more than 30 seconds) during the first week after surgery;	—

Secondary

Measure	Time frame
Atrial fibrillation load;Onset time of atrial fibrillation;Maximum ventricular rate during atrial fibrillation;Mean ventricular rate during atrial fibrillation;Postoperative ventilator support time (h) ICU stay time (h) postoperative hospital stay (d);Inflammatory and oxidative stress indicators: IL-6, CRP, TNF-a, PCT, MDA, SOD;Drug use and control during atrial fibrillation, circulatory index;	—

Countries

China

Contacts

Public ContactHuishan Wang

Department of cardiovascular surgery, General Hospital of Northern Theater Command

huishanw@126.com+86 13309885095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026